Interferons (alpha), Peginterferon, Ropeginterferon

RISK OF SERIOUS DISORDERS

Risk of Serious Disorders

• Alpha interferons, including peginterferon alfa-2a, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders.
• Patients should be monitored closely with periodic clinical and laboratory evaluations.
• Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions.
• In many, but not all cases, these disorders resolve after stopping therapy

MONITORING RECOMMENDATIONS RELATED TO BLACK BOX DATA

• Close monitoring of depressive symptomatology and periodic neuropsychiatric evaluation during therapy.
• Persistent severe or worsening signs or symptoms may necessitate discontinuation of therapy

Patient Counseling Information

• Besremi

• Interferon Alfacon-1

• Intron A

• Pegasys

• Roferon-A

Medication Guides

Patient Medication Guide - Itron A (Interferon Alfa-2b)

Patient Medication Guide - BESREMI (Ropeginterferon Alfa-2b-Nift)

Package Inserts

Interferons and Peginterferons

Additional Information

Interferon Alfa-2b (Intron A) products have been discontinued.